Chugai Pharmaceutical EBITDA vs. Price To Sales
| CHGCY Stock | USD 21.47 0.60 2.72% |
For Chugai Pharmaceutical profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Chugai Pharmaceutical to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Chugai Pharmaceutical Co utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Chugai Pharmaceutical's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Chugai Pharmaceutical Co over time as well as its relative position and ranking within its peers.
Chugai |
Chugai Pharmaceutical Price To Sales vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Chugai Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Chugai Pharmaceutical value to that of its competitors to determine the firm's financial worth. Chugai Pharmaceutical Co is number one stock in ebitda category among its peers. It is rated fifth in price to sales category among its peers . The ratio of EBITDA to Price To Sales for Chugai Pharmaceutical Co is about Huge . Comparative valuation analysis is a catch-all model that can be used if you cannot value Chugai Pharmaceutical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Chugai Pharmaceutical's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Chugai Price To Sales vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Chugai Pharmaceutical |
| = | 419.43 B |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Chugai Pharmaceutical |
| = | 0.04 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Chugai Price To Sales Comparison
Chugai Pharmaceutical is currently under evaluation in price to sales category among its peers.
Chugai Pharmaceutical Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Chugai Pharmaceutical, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Chugai Pharmaceutical will eventually generate negative long term returns. The profitability progress is the general direction of Chugai Pharmaceutical's change in net profit over the period of time. It can combine multiple indicators of Chugai Pharmaceutical, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd. CHUGAI PHARMACEUTICAL operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 7664 people.
Chugai Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Chugai Pharmaceutical. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Chugai Pharmaceutical position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Chugai Pharmaceutical's important profitability drivers and their relationship over time.
Use Chugai Pharmaceutical in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Chugai Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Chugai Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Chugai Pharmaceutical Pair Trading
Chugai Pharmaceutical Co Pair Trading Analysis
The ability to find closely correlated positions to Chugai Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Chugai Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Chugai Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Chugai Pharmaceutical Co to buy it.
The correlation of Chugai Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Chugai Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Chugai Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Chugai Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Chugai Pharmaceutical position
In addition to having Chugai Pharmaceutical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Russia On Wall Street Thematic Idea Now
Russia On Wall Street
Cross-sector and cross-instrument bundle of publicly traded Russian entities that are expected to be listed on USA exchanges or over the counter. The Russia On Wall Street theme has 23 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Russia On Wall Street Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Chugai Pink Sheet Analysis
When running Chugai Pharmaceutical's price analysis, check to measure Chugai Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chugai Pharmaceutical is operating at the current time. Most of Chugai Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Chugai Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chugai Pharmaceutical's price. Additionally, you may evaluate how the addition of Chugai Pharmaceutical to your portfolios can decrease your overall portfolio volatility.